{
    "Trade/Device Name(s)": [
        "Dexcom G7 Continuous Glucose Monitoring System",
        "Dexcom G7 CGM System",
        "G7 System"
    ],
    "Submitter Information": "Dexcom Inc.",
    "510(k) Number": "K234133",
    "Predicate Device Reference 510(k) Number(s)": [
        "K231081"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "QBJ",
        "KGX"
    ],
    "Summary Letter Date": "February 26, 2024",
    "Summary Letter Received Date": "December 29, 2023",
    "Submission Date": "December 28, 2023",
    "Regulation Number(s)": [
        "21 CFR 862.1355"
    ],
    "Regulation Name(s)": [
        "Integrated continuous glucose monitoring system"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "endocrine",
        "POCT"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Interstitial fluid"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "G7 sensor",
        "G7 transmitter",
        "G7 Mobile Application (iOS/Android)",
        "G7 Receiver",
        "Compatible iOS smartwatches"
    ],
    "Method(s)/Technology(ies)": [
        "Wire-type sensing mechanism",
        "Continuous glucose monitoring",
        "Wireless data transmission"
    ],
    "Methodologies": [
        "Continuous monitoring",
        "Factory calibrated sensing"
    ],
    "Submission Type(s)": [
        "System",
        "Sensor",
        "Transmitter",
        "Mobile Application",
        "Receiver",
        "Software"
    ],
    "Document Summary": "FDA 510(k) summary for Dexcom G7 Continuous Glucose Monitoring System with direct-to-watch feature for continuous real-time glucose monitoring",
    "Indications for Use Summary": "Intended for real-time management of diabetes in persons 2 years and older by replacing fingerstick testing and detecting hyperglycemia/hypoglycemia; communicates with compatible digital devices including automated insulin dosing systems.",
    "fda_folder": "Clinical Chemistry"
}